Author information

¹Organ Transplantation Center, National Center for Child Health and Development, Tokyo, Japan. Electronic address: kasahara-m@ncchd.go.jp.

²Division of Transplant Surgery, Department of Surgery, Medical College of Wisconsin, Milwaukee, USA.

³Paediatric Liver GI and Nutrition Center and MowatLabs, King's College Hospital, London, UK.

Abstract

Living donor liver transplantation (LDLT) is recognised as an alternative treatment modality to reduce waiting list mortality and expand the donor pool. Over recent decades, there have been an increasing number of reports on the use of LT and specifically LDLT for familial hereditary liver diseases. There are marginal indications and contraindications that should be considered for a living donor in paediatric parental LDLT. No mortality or morbidity related to recurrence of metabolic diseases has been observed with heterozygous donors, except for certain relevant cases, such as ornithine transcarbamylase deficiency, protein C deficiency, hypercholesterolemia, protoporphyria, and Alagille syndrome, while donor human leukocyte antigen homozygosity also poses a risk. It is not always essential to perform preoperative genetic assays for possible heterozygous carriers; however, genetic and enzymatic assays must hereafter be included in the parental donor selection criteria in the aforementioned circumstances.